Another clinical trial (Phase I; NCT01591356) is investigating the effects of an siRNA against EphA2 (Ephrin receptor A2) (EphA2-targeting DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine)-siRNA), a protein that is associated with driving migratory and invasive patterns of tumor cells, to treat patients with several forms of advanced malignant solid neoplasm. Here, EPHA2 is linked to neoplasm.